Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Monogram Orthopaedics Inc ( (MGRM) ) is now available.
On July 11, 2025, Monogram Technologies Inc. entered into a merger agreement with Zimmer Biomet Holdings, Inc., where Monogram will become a wholly-owned subsidiary. The merger involves converting Monogram’s stock into cash and contingent value rights, with the merger subject to conditions such as stockholder approval and regulatory clearance. The merger will result in Monogram’s delisting from Nasdaq and includes provisions for potential alternative offers and a termination fee if the merger is not completed by January 11, 2026.
The most recent analyst rating on (MGRM) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Monogram Orthopaedics Inc stock, see the MGRM Stock Forecast page.
Spark’s Take on MGRM Stock
According to Spark, TipRanks’ AI Analyst, MGRM is a Neutral.
Monogram Orthopaedics Inc. shows promise due to significant technological advancements and recent regulatory clearances, which are key drivers for potential growth. However, financial instability, regulatory uncertainties, and ongoing profitability challenges weigh heavily on the overall score. The stock’s upward momentum is a positive indicator, but valuation metrics remain weak due to negative earnings and lack of dividends.
To see Spark’s full report on MGRM stock, click here.
More about Monogram Orthopaedics Inc
Average Trading Volume: 59,828
Technical Sentiment Signal: Strong Buy
For an in-depth examination of MGRM stock, go to TipRanks’ Overview page.